(Axios) – A fightis brewing between drug giantsand pharmacy compounders that have seized on the consumer demand for blockbuster obesity drugs. Why it matters: The clash is testing the boundaries of Food and Drug Administration policy that allows pharmacies to make versions of drugs — including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy — that are otherwise protected by patents when there are shortages. (Read More)